The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2026 | GLEAM: biomarker and pharmacokinetic analyses of zolbetuximab in PAC
Michel Ducreux, MD, PhD, Paris-Saclay University, Paris, France, discusses pharmacokinetic and biomarker analyses from the Phase II GLEAM study (NCT03816163) of zolbetuximab plus gemcitabine and nab-paclitaxel in claudin 18.2-positive metastatic pancreatic adenocarcinoma (PAC). Drug exposure was comparable to that seen in gastric and gastroesophageal junction cancer, suggesting reduced efficacy in pancreatic cancer relates to disease- or chemotherapy-specific factors. Zolbetuximab increased immune-related cytokine levels during treatment, with greater interleukin-18 elevation associated with longer overall survival. This interview took place at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancer 2026 Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
